7/103 sources · 2 publishersUpdated Oct 8, 21:21 UTC
Barclays cuts uniQure rating to Equal Weight and lowers price target
Barclays analyst Eliana Merle downgraded uniQure (QURE) from Overweight to Equal Weight on October 5, 2026. The downgrade came with a price‑target reduction from $60.00 to $28.00. RBC also trimmed its price target to $48 from $65 while keeping an Outperform rating. UniQure’s shares fell to $22.81, down 2.77% on the day.
Why it matters
Barclays’ lower target suggests a more cautious outlook for the gene‑therapy company, which could pressure the stock further. RBC’s reduced target also signals weaker expectations for future performance.
Key facts
- 1Barclays downgraded uniQure to Equal Weight from Overweight on 2026‑10‑05. marketscreener.com
- 2Barclays cut its price target from $60.00 to $28.00, a 53.33% decrease. gurufocus.com
- 3RBC lowered its price target to $48 from $65, maintaining an Outperform rating. marketscreener.com
- 4UniQure’s share price was $23.46 at the time of the Barclays downgrade. marketscreener.com
- 5UniQure’s share price fell to $22.81, down 2.77% on the day. marketscreener.com
- 6UniQure’s stock is down 38.63% year‑to‑date. marketscreener.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.